GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (FRA:OQS) » Definitions » Beta

Nanosonics (FRA:OQS) Beta : 2.20 (As of Dec. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Nanosonics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-14), Nanosonics's Beta is 2.20.


Nanosonics Beta Historical Data

The historical data trend for Nanosonics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanosonics Beta Chart

Nanosonics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 1.34 1.34 1.95 2.22

Nanosonics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 1.70 1.95 2.05 2.22

Competitive Comparison of Nanosonics's Beta

For the Medical Instruments & Supplies subindustry, Nanosonics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanosonics's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Beta distribution charts can be found below:

* The bar in red indicates where Nanosonics's Beta falls into.



Nanosonics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Nanosonics  (FRA:OQS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Nanosonics Beta Related Terms

Thank you for viewing the detailed overview of Nanosonics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanosonics Business Description

Traded in Other Exchanges
Address
7-11 Talavera Road, Level 1 Building A, Macquarie Park, Sydney, NSW, AUS, 2113
Nanosonics is a single-product firm and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue is made up of capital sales of Trophon units, ongoing consumables sales, and service revenue. By June 2022, there were 29,850 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, about 44% in the US to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.

Nanosonics Headlines

No Headlines